Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in a report published on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.

ACRS has been the subject of several other research reports. Jefferies Group LLC reissued a buy rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a research report on Wednesday, June 28th. BidaskClub raised shares of Aclaris Therapeutics from a hold rating to a buy rating in a research report on Monday, July 24th. ValuEngine downgraded shares of Aclaris Therapeutics from a hold rating to a sell rating in a research report on Tuesday, June 6th. Guggenheim reissued a buy rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. Finally, JMP Securities reissued an outperform rating and issued a $39.00 price target on shares of Aclaris Therapeutics in a research report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Aclaris Therapeutics currently has a consensus rating of Buy and a consensus price target of $41.25.

Aclaris Therapeutics (NASDAQ:ACRS) opened at 27.61 on Wednesday. The stock has a 50 day moving average of $25.92 and a 200 day moving average of $27.19. Aclaris Therapeutics has a 12-month low of $20.15 and a 12-month high of $33.25. The firm’s market cap is $738.18 million.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.12. On average, equities research analysts anticipate that Aclaris Therapeutics will post ($3.10) EPS for the current fiscal year.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/cantor-fitzgerald-analysts-give-aclaris-therapeutics-inc-acrs-a-50-00-price-target/1614197.html.

In other Aclaris Therapeutics news, Director Andrew N. Schiff purchased 108,601 shares of Aclaris Therapeutics stock in a transaction that occurred on Wednesday, August 16th. The stock was acquired at an average price of $23.02 per share, with a total value of $2,499,995.02. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 16.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors grew its position in Aclaris Therapeutics by 8.3% in the 1st quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 510 shares during the period. American International Group Inc. boosted its holdings in Aclaris Therapeutics by 31.3% during the 1st quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 1,623 shares during the last quarter. UBS Group AG boosted its holdings in Aclaris Therapeutics by 60.4% during the 1st quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 1,681 shares during the last quarter. Alps Advisors Inc. boosted its holdings in Aclaris Therapeutics by 7.7% during the 2nd quarter. Alps Advisors Inc. now owns 24,129 shares of the biotechnology company’s stock worth $654,000 after acquiring an additional 1,718 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Aclaris Therapeutics by 24.0% during the 1st quarter. Alliancebernstein L.P. now owns 9,300 shares of the biotechnology company’s stock worth $277,000 after acquiring an additional 1,800 shares during the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.